The mitochondrion as a key regulator of ischaemic tolerance and injury

Heart Lung and Circulation

Volumn 23, Issue 10, 2014, Pages 897-904

  Silachev, Denis N ^a   Plotnikov, Egor Y ^a   Pevzner, Irina B ^a   Zorova, Ljubava D ^a   Babenko, Valentina A ^a,b   Zorov, Savva D ^a   Popkov, Vasily A ^a   Jankauskas, Stanislovas S ^a   Zinchenko, Valery P ^c   Sukhikh, Gennady T ^b   Zorov, Dmitry B ^a  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b RESEARCH CENTER OF OBSTETRICS   (Russian Federation)

^c INSTITUTE OF CELL BIOPHYSICS   (Russian Federation)

Author keywords

Antioxidants; Brain; Heart; Kidney; Preconditioning; Reperfusion

Indexed keywords

ANTIOXIDANT; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; CELL DAMAGE; CELL PROTECTION; DISEASE ASSOCIATION; DRUG ACTIVITY; HEART INJURY; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPOXIA; ISCHEMIC PRECONDITIONING; MITOCHONDRION; OXIDATIVE STRESS; OXYGEN TISSUE LEVEL; POTASSIUM TRANSPORT; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; HEART INFARCTION PREVENTION; HEART MITOCHONDRION; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PHYSIOLOGY; PROCEDURES;

HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MITOCHONDRIA, HEART; MYOCARDIAL REPERFUSION INJURY; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84907764176     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2014.05.022     Document Type: Review

References (71)

1. Global atlas on cardiovascular disease prevention and control. Geneva, World Health Organization, 2011.
2. Feigin V.L., Forouzanfar M.H., Krishnamurthi R., Mensah G.A., Connor M., Bennett D.A., et al. Global and regional burden of stroke during 1990-2010: findings from the global burden of disease study 2010. Lancet 2014, 383(9913):245-254.
3. Schneider A., Bottiger B.W., Popp E. Cerebral resuscitation after cardiocirculatory arrest. Anesth Analg 2009, 108(3):971-979.
4. Susantitaphong P., Cruz D.N., Cerda J., Abulfaraj M., Alqahtani F., Koulouridis I., et al. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013, 8(9):1482-1493.
5. Himmelfarb J., Ikizler T.A. Acute kidney injury: changing lexicography, definitions, and epidemiology. Kidney Int 2007, 71(10):971-976.
6. Cadenas E., Sies H. Oxidative stress: excited oxygen species and enzyme activity. Adv Enzyme Regul 1985, 23:217-237.
7. Plotnikov E.Y., Kazachenko A.V., Vyssokikh M.Y., Vasileva A.K., Tcvirkun D.V., Isaev N.K., et al. The role of mitochondria in oxidative and nitrosative stress during ischemia/reperfusion in the rat kidney. Kidney Int 2007, 72(12):1493-1502.
8. Zorov D.B., Juhaszova M., Sollott S.J. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 2014, 94(3):909-950.
9. Rajasekaran N.S., Connell P., Christians E.S., Yan L.J., Taylor R.P., Orosz A., et al. Human alpha b-crystallin mutation causes oxido-reductive stress and protein aggregation cardiomyopathy in mice. Cell 2007, 130(3):427-439.
10. Wittenberg J.B., Wittenberg B.A. Myoglobin-enhanced oxygen delivery to isolated cardiac mitochondria. J Exp Biol 2007, 210:2082-2090.
11. Krogh A. The supply of oxygen to the tissues and the regulation of the capillary circulation. J Physiol 1919, 52(6):457-474.
12. 2+ -dependent collapse of mitochondrial membrane potential and ultrastructural alterations of mitochondria. FEBS Lett 1996, 392(2):143-147.
13. 2 sensing: the search continues. Am J Physiol Lung Cell Mol Physiol 2002, 283(5):L918-L921.
14. Waypa G.B., Schumacker P.T. O(2) sensing in hypoxic pulmonary vasoconstriction: the mitochondrial door re-opens. Respir Physiol Neurobiol 2002, 132(1):81-91.
15. Hearse D.J., Garlick P.B., Humphrey S.M. Ischemic contracture of the myocardium: mechanisms and prevention. Am J Cardiol 1977, 39(7):986-993.
16. Zorov D.B., Filburn C.R., Klotz L.O., Zweier J.L., Sollott S.J. Reactive oxygen species (ros)-induced ros release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med 2000, 192(7):1001-1014.
17. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002, 82(1):47-95.
18. Zorov D.B., Isaev N.K., Plotnikov E.Y., Silachev D.N., Zorova L.D., Pevzner I.B., et al. Perspectives of mitochondrial medicine. Biochemistry (Mosc). 2013, 78(9):979-990.
19. Ratych R.E., Bulkley G.B. Free-radical-mediated postischemic reperfusion injury in the kidney. J Free Radic Biol Med 1986, 2(5-6):311-319.
20. Zorov D.B., Juhaszova M., Sollott S.J. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta. 2006, 1757(5-6):509-517.
21. Hess M.L., Manson N.H. Molecular oxygen: friend and foe. The role of the oxygen free radical system in the calcium paradox, the oxygen paradox and ischemia/reperfusion injury. J Mol Cell Cardiol 1984, 16(11):969-985.
22. Zorov D.B., Krasnikov B.F., Kuzminova A.E., Vysokikh MYu, Zorova L.D. Mitochondria revisited. Alternative functions of mitochondria. Biosci Rep 1997, 17(6):507-520.
23. Zorov D.B., Plotnikov E.Y., Jankauskas S.S., Isaev N.K., Silachev D.N., Zorova L.D., et al. The phenoptosis problem: what is causing the death of an organism? Lessons from acute kidney injury. Biochemistry (Mosc) 2012, 77(7):742-753.
24. Collins R., Armitage J., Parish S., Sleight P., Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363(9411):757-767.
25. Kromhout D. Diet and cardiovascular diseases. J Nutr Health Aging 2001, 5(3):144-149.
26. Lowes D.A., Thottakam B.M., Webster N.R., Murphy M.P., Galley H.F. The mitochondria-targeted antioxidant mitoq protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic Biol Med 2008, 45(11):1559-1565.
27. Rokitskaya T.I., Klishin S.S., Severina I.I., Skulachev V.P., Antonenko Y.N. Kinetic analysis of permeation of mitochondria-targeted antioxidants across bilayer lipid membranes. J Membr Biol 2008, 224(1-3):9-19.
28. Plotnikov E.Y., Silachev D.N., Chupyrkina A.A., Danshina M.I., Jankauskas S.S., Morosanova M.A., et al. New-generation skulachev ions exhibiting nephroprotective and neuroprotective properties. Biochemistry (Mosc) 2010, 75(2):145-150.
29. Bakeeva L.E., Barskov I.V., Egorov M.V., Isaev N.K., Kapelko V.I., Kazachenko A.V., et al. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 2. Treatment of some ROS- and age-related diseases (heart arrhythmia, heart infarctions, kidney ischemia, and stroke). Biochemistry (Mosc) 2008, 73(12):1288-1299.
30. Plotnikov E.Y., Chupyrkina A.A., Jankauskas S.S., Pevzner I.B., Silachev D.N., Skulachev V.P., et al. Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion. Biochim Biophys Acta 2011, 1812(1):77-86.
31. Plotnikov E.Y., Morosanova M.A., Pevzner I.B., Zorova L.D., Manskikh V.N., Pulkova N.V., et al. Protective effect of mitochondria-targeted antioxidants in an acute bacterial infection. Proc Natl Acad Sci U S A 2013, 110(33):E3100-E3108.
32. Silachev D.N., Isaev N.K., Pevzner I.B., Zorova L.D., Stelmashook E.V., Novikova S.V., et al. The mitochondria-targeted antioxidants and remote kidney preconditioning ameliorate brain damage through kidney-to-brain cross-talk. PLoS One 2012, 7(12):e51553.
33. Kapay N.A., Isaev N.K., Stelmashook E.V., Popova O.V., Zorov D.B., Skrebitsky V.G., et al. In vivo injected mitochondria-targeted plastoquinone antioxidant skqr1 prevents beta-amyloid-induced decay of long-term potentiation in rat hippocampal slices. Biochemistry (Mosc) 2011, 76(12):1367-1370.
34. McManus M.J., Murphy M.P., Franklin J.L. The mitochondria-targeted antioxidant mitoq prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of alzheimer's disease. J Neurosci 2011, 31(44):15703-15715.
35. Covey M.V., Murphy M.P., Hobbs C.E., Smith R.A., Oorschot D.E. Effect of the mitochondrial antioxidant, mito vitamin e, on hypoxic-ischemic striatal injury in neonatal rats: a dose-response and stereological study. Exp Neurol 2006, 199(2):513-519.
36. Mitchell T., Rotaru D., Saba H., Smith R.A., Murphy M.P., MacMillan-Crow L.A. The mitochondria-targeted antioxidant mitoquinone protects against cold storage injury of renal tubular cells and rat kidneys. J Pharmacol Exp Ther 2011, 336(3):682-692.
37. Chacko B.K., Reily C., Srivastava A., Johnson M.S., Ye Y., Ulasova E., et al. Prevention of diabetic nephropathy in ins2(+/)(-)(akitaj) mice by the mitochondria-targeted therapy mitoQ. Biochem J 2010, 432(1):9-19.
38. Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W., et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004, 113(11):1535-1549.
39. Hunter D.R., Haworth R.A. The ca2+-induced membrane transition in mitochondria. I. The protective mechanisms. Arch Biochem Biophys 1979, 195(2):453-459.
40. Zorov D.B., Juhaszova M., Yaniv Y., Nuss H.B., Wang S., Sollott S.J. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc Res 2009, 83(2):213-225.
41. Stambolic V., Ruel L., Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996, 6(12):1664-1668.
42. Beutner G., Ruck A., Riede B., Welte W., Brdiczka D. Complexes between kinases, mitochondrial porin and adenylate translocator in rat brain resemble the permeability transition pore. FEBS Lett 1996, 396(2-3):189-195.
43. Brdiczka D.G., Zorov D.B., Sheu S.S. Mitochondrial contact sites: their role in energy metabolism and apoptosis. Biochim Biophys Acta 2006, 1762(2):148-163.
44. Kokoszka J.E., Waymire K.G., Levy S.E., Sligh J.E., Cai J., Jones D.P., et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004, 427(6973):461-465.
45. Basso E., Fante L., Fowlkes J., Petronilli V., Forte M.A., Bernardi P. Properties of the permeability transition pore in mitochondria devoid of cyclophilin d. J Biol Chem 2005, 280(19):18558-18561.
46. Benveniste H., Drejer J., Schousboe A., Diemer N.H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984, 43(5):1369-1374.
47. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003, 285(2):H579-H588.
48. Juhaszova M., Rabuel C., Zorov D.B., Lakatta E.G., Sollott S.J. Protection in the aged heart: preventing the heart-break of old age?. Cardiovasc Res 2005, 66(2):233-244.
49. Argaud L., Gateau-Roesch O., Raisky O., Loufouat J., Robert D., Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005, 111(2):194-197.
50. ATP, PKCepsilon, ROS, and MPT. Am J Physiol Heart Circ Physiol 2008, 295(2):H874-H882.
51. ATP channel. Annu Rev Physiol 2000, 62:79-109.
52. Tapuria N., Kumar Y., Habib M.M., Abu Amara M., Seifalian A.M., Davidson B.R. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury--a review. J Surg Res 2008, 150(2):304-330.
53. McClanahan T.B., Nao B.S., Wolke L.J., Martin B.J., Mertz T.E., Gallagher K.P. Brief renal occlusion and reperfusion induces myocardial infarct size in rabbits. FASEB J 1993, 7:A118.
54. Weinbrenner C., Nelles M., Herzog N., Sarvary L., Strasser R.H. Remote preconditioning by infrarenal occlusion of the aorta protects the heart from infarction: a newly identified non-neuronal but PKC-dependent pathway. Cardiovasc Res 2002, 55(3):590-601.
55. Zhang S.Z., Wang N.F., Xu J., Gao Q., Lin G.H., Bruce I.C., et al. Kappa-opioid receptors mediate cardioprotection by remote preconditioning. Anesthesiology 2006, 105(3):550-556.
56. Hu S., Dong H., Zhang H., Wang S., Hou L., Chen S., et al. Noninvasive limb remote ischemic preconditioning contributes neuroprotective effects via activation of adenosine A1 receptor and redox status after transient focal cerebral ischemia in rats. Brain Res 2012, 1459:81-90.
57. Waldow T., Alexiou K., Witt W., Albrecht S., Wagner F., Knaut M., et al. Protection against acute porcine lung ischemia/reperfusion injury by systemic preconditioning via hind limb ischemia. Transpl Int 2005, 18(2):198-205.
58. Takaoka A., Nakae I., Mitsunami K., Yabe T., Morikawa S., Inubushi T., et al. Renal ischemia/reperfusion remotely improves myocardial energy metabolism during myocardial ischemia via adenosine receptors in rabbits: effects of "remote preconditioning". J Am Coll Cardiol 1999, 33(2):556-564.
59. Singh D., Chopra K. Evidence of the role of angiotensin AT(1) receptors in remote renal preconditioning of myocardium. Methods Find Exp Clin Pharmacol 2004, 26(2):117-122.
60. Pell T.J., Baxter G.F., Yellon D.M., Drew G.M. Renal ischemia preconditions myocardium: role of adenosine receptors and atp-sensitive potassium channels. Am J Physiol 1998, 275(5 Pt 2):H1542-H1547.
61. Patel H.H., Moore J., Hsu A.K., Gross G.J. Cardioprotection at a distance: mesenteric artery occlusion protects the myocardium via an opioid sensitive mechanism. J Mol Cell Cardiol 2002, 34(10):1317-1323.
62. Diwan V., Jaggi A.S., Singh M., Singh N., Singh D. Possible involvement of erythropoietin in remote renal preconditioning-induced cardioprotection in rats. J Cardiovasc Pharmacol 2008, 51(2):126-130.
63. Schoemaker R.G., van Heijningen C.L. Bradykinin mediates cardiac preconditioning at a distance. Am J Physiol Heart Circ Physiol 2000, 278(5):H1571-H1576.
64. Kristiansen S.B., Henning O., Kharbanda R.K., Nielsen-Kudsk J.E., Schmidt M.R., Redington A.N., et al. Remote preconditioning reduces ischemic injury in the explanted heart by a katp channel-dependent mechanism. Am J Physiol Heart Circ Physiol 2005, 288(3):H1252-H1256.
65. + channel: a novel therapeutic target in unstable angina. Eur Heart J 1999, 20(1):2-5.
66. Mentzer R.M., Rahko P.S., Molina-Viamonte V., Canver C.C., Chopra P.S., Love R.B., et al. Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery. Am J Cardiol 1997, 79(12A):38-43.
67. Mahaffey K.W., Puma J.A., Barbagelata N.A., DiCarli M.F., Leesar M.A., Browne K.F., et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the acute myocardial infarction study of adenosine (amistad) trial. J Am Coll Cardiol 1999, 34(6):1711-1720.
68. Cason B.A., Gamperl A.K., Slocum R.E., Hickey R.F. Anesthetic-induced preconditioning: previous administration of isoflurane decreases myocardial infarct size in rabbits. Anesthesiology 1997, 87(5):1182-1190.
69. Minguet G., Joris J., Lamy M., Preconditioning protection against ischaemia-reperfusion in non-cardiac organs: a place for volatile anaesthetics?. Eur J Anaesthesiol 2007, 24(9):733-745.
70. De Hert S., Vlasselaers D., Barbe R., Ory J.P., Dekegel D., Donnadonni R., et al. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia 2009, 64(9):953-960.
71. Kapinya K.J., Lowl D., Futterer C., Maurer M., Waschke K.F., Isaev N.K., et al. Tolerance against ischemic neuronal injury can be induced by volatile anesthetics and is inducible no synthase dependent. Stroke 2002, 33(7):1889-1898.